Showing results (271-280 of 349) with videos related to
Sort By:
Pageof 35
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 21, 2003
Brain penetration of aprepitant, a substance P receptor antagonist, in ferretsSu-Er W Huskey, Brian J Dean, Ray Bakhtiar, et al.Radiology|July 28, 2026
Contrast-enhanced Mammography for Breast Cancer Screening in Women at Increased Risk: Comparison of Prevalence and Incidence ScreensCarol H Lee, Tali Amir, Varadan Sevilimedu, et al.Journal of the American Chemical Society|April 10, 2023
A Manganese Compound I Model with a High Reactivity in the Oxidation of Organic Substrates and WaterLina Zhang, Mi Sook Seo, Yunhee Choi, et al.ACS Medicinal Chemistry Letters|August 27, 2016
CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis ModelAndrew D Cansfield, Tammy Ladduwahetty, Mihiro Sunose, et al.Bioorganic & Medicinal Chemistry Letters|May 17, 2001
2-Aryl indole NK1 receptor antagonists: optimisation of indole substitutionL C Cooper, G G Chicchi, K Dinnell, et al.Open Forum Infectious Diseases|July 7, 2018
Obesity, Diabetes, and the Risk of Invasive Group B Streptococcal Disease in Nonpregnant Adults in the United StatesSamantha I Pitts, Nisa M Maruthur, Gayle E Langley, et al.JNCI Cancer Spectrum|April 2, 2024
Association of breast cancer with quantitative mammographic density measures for women receiving contrast-enhanced mammographyGordon P Watt, Krishna N Keshavamurthy, Tuong L Nguyen, et al.Journal of Medicinal Chemistry|March 3, 1999
3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agentsM S Chambers, L J Street, S Goodacre, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 16, 2021
Racial Disparities in Invasive Haemophilus influenzae Disease-United States, 2008-2017Nicole E Brown, Amy E Blain, Kari Burzlaff, et al.Journal of Medicinal Chemistry|February 16, 1996
Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureasJ L Castro, R G Ball, H B Broughton, et al.Pageof 35